Regeneron: Antibody cocktail helps prevent symptomatic COVID-19
The monoclonal antibody therapy REGEN-COV (casirivimab with imdevimab) reduced the risk of symptomatic COVID-19 in household contacts of people with SARS-CoV-2 by 81% in a phase 3 clinical trial conducted with the National Institute of Allergy and Infectious Diseases, Regeneron Pharmaceuticals announced yesterday.
The Food and Drug Administration has authorized emergency use of the therapy for people at high risk of progressing to severe COVID-19 or hospitalization. The company plans to ask the agency to expand the EUA to include COVID-19 prevention.
Related News Articles
Headline
CDC issues reminder on ending of the emergency authorization for COVID-19 in vitro diagnostics tests
The Centers for Disease Control and Prevention issued a reminder Oct. 14 that the declaration supporting the emergency use of COVID-19 in vitro diagnostics…
Headline
The Department of Health of Human Services Aug. 21 issued a request for information seeking feedback on immunization categories within the Aug. 10 executive…
Headline
For the 2025-2026 school year, exemptions from one or more vaccines among U.S. kindergartners was at 4.2%, increasing from 3.6% for the previous school year,…
Headline
A study published Aug. 5 by Nature found that COVID-19 infection can reactivate dormant, chronic viruses such as Epstein-Barr and cytomegalovirus. The study…
Headline
The Department of Health and Human Services June 30 announced it will terminate emergency use authorization declarations for certain drugs and medical devices…
Headline
Centers for Medicare & Medicaid Services Administrator Mehmet Oz, M.D., and CMS Deputy Administrator and Director of Medicaid and CHIP Dan Brillman sat…